Full-Time

Senior Clinical Data Manager

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$158k - $198kAnnually

Senior

San Carlos, CA, USA

This position is hybrid, requiring some in-office days.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

You match the following Revolution Medicines's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in health sciences, Life Sciences, Mathematics, Computer Sciences, or health-related field.
  • At least three years for CDM and five years for Sr. CDM of Data Management experience in the pharmaceutical or biotechnology industry, depth and exposure to DM related tasks considered in lieu of minimum requirement.
  • Requires solid knowledge of clinical data management principles, clinical trials process and regulatory requirements.
  • Good working knowledge of ICH, FDA, and GCP regulations and guidelines.
  • Strong well-rounded technical skills (EDC systems, MS Word, Excel, PowerPoint).
  • Knowledge of industry standards (CDISC, SDTM, CDASH).
  • Experience with web-based Electronic Data Capture (EDC), clinical data management systems and industry wide thesauri, such as MedDRA and WHO Drug.
  • Excellent verbal/written and interpersonal skills required for working successfully in a cross-functional team environment.
  • Ability to handle multiple projects and prioritize effectively, well organized and detail oriented.
  • Proven ability to work both independently and in a team setting.
Responsibilities
  • Represents data management in study team meetings, able to facilitate and provide data management updates and/or input when appropriate.
  • Manages data management timelines to coordinate and synchronize deliverables with the overall study timelines.
  • Generates and/or reviews/approves study documents (e.g. Data Management Plans, Case Report Forms, DB build specifications, data transfer specifications, SAE and/or external data reconciliation plans, coding conventions, laboratory data handling plan, study protocols).
  • Reviews protocols for appropriate data capture including electronic Case Report Form (eCRF) design and external data vendors’ systems.
  • Provides oversight of database set-up/migrations/updates including coordinating and performing UAT.
  • Leads the development of internal Data Review Plan and coordinates cross functional team data listing review.
  • Coordinates the internal medical coding review.
  • Performs ad hoc and scheduled data listing review and generates/resolves queries in EDC.
  • Performs external data reconciliation against EDC.
  • Performs Serious AE reconciliation according to SOPs and guidelines, as applicable.
  • Executes and/or distributes data management metrics, listings, and reports.
  • Provides oversight of data management CRO/service providers including manages and monitors the progress of data management activities with CROs and/or other service providers on assigned studies; build effective relationships with CRO/service provider counterparts.
  • Reviews and provides feedback to the clinical team on other study documents e.g., Clinical Monitoring plans and vendor specifications.
  • Provides training on the EDC system and/or CRF completion guidelines and EDC system to internal or external study team members, as needed.
  • Proactively identifies potential study issues/risks and recommends/implements solutions.
  • Maintains study DM related documents/files for inspection readiness.
  • Provides DM support to Statisticians and Statistical Programmers in production of clinical trial reports and other deliverables.
  • Assists with the training of new employees and/or contractors (e.g., clinical data associates and/or junior clinical data managers working on the studies).
  • Participates in CRO/vendor selection process for outsourced activities.
  • Supports budget and resource planning across assigned projects.
  • Participates in the development, review and implementation of departmental SOPs, templates, and processes.
  • Participates in department or cross-functional initiatives (as needed).
  • Contributes to a professional working environment through exemplifying RevMed Core Values.
Desired Qualifications
  • CRO/Service provider management experience.
  • Prior oncology/solid tumor experience highly desired.
  • Working knowledge of statistical programming packages (e.g. SAS) is a plus.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

7%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.